Institut Paoli Calmettes IPC is a comprehensive cancer

Institut Paoli Calmettes (IPC) is a comprehensive cancer center with three missions: patient care, research and education - Private non for profit hospital French Network (Unicancer: 18 cancer centers) Budget: 209 M€ 1 550 staff including 400 people in research 10 273 new patients/year

Research at Institut Paoli Calmettes Prof Jean-Paul Borg Scientific Director

Topics Basic Science Skin 113 Bone 20 Other 100 102 ENT 75 Endocrino 285 Thorax 407 Urology 347 Breast : 1776 Male reproductive 632 Gynecology 605 Translational Research Clinical Research Digestive 1501 Hematology 1233 Cancer & Society

Geography CRCM (Center for Cancer Research of Marseille) – 19 teams IPC - Inserm - CNRS - Aix Marseille University Department of Cancer Biology SESSTIM - Cancer Biomedicine & Society team (Can. Bio. S) Inserm - IRD - Aix Marseille University Clinical research Office CLIP 2: Personalized approaches and strategies of innovative research for early phase trials in medical oncology and hematology Technological platforms – 15 facilities

Objectives Basic Science Medical Science A basic-translational-clinical continuum in cancer research Development of cutting-edge platforms and resources Industrial transfer CRCM Education Technology Resources Collaborative programs with industries and technology transfer Training of Scientists, MDs and Pharm. Ds

Technologies and platforms - Cell imaging Animal facility and transgenesis Preclinical platform (Tr. GET) Flow cytometry and cell sorting Bioinformatics, Biostatistics Experimental histo-pathology Genomics and sequencing Cell culture Datacentre IT and Scientific Computing Department of Clinical Research and Development Data management and analysis center Biotherapy and Cell therapy DOSynth Chemical synthesis platform SMARTc Simulation & Modelling of adaptive response in therapeutics in cancer - Early Phase Trial center (ETOH) Nanobodies Proteomics Immunomonitoring Biological Resource Centre Medical Science Basic Science Industrial transer CRCM Technology resources Education

Attractiveness number of group leaders 20 newly recruited scientists 18 16 Total number of scientists 14 400 12 350 10 300 8 250 6 200 4 100 150 50 2 0 0 2012 2013 2014 2015 2016 2017 2018 2012 2013 2017 2018 20 teams - 400 people 60 MDs/Pharm. Ds in research 26 nationalities

Platforms and ressources - Cell imaging - Animal house and transgenesis - Preclinical platform (Tr. GET) - Flow cytometry and cell sorting - Bioinformatics, Biostatistics - Experimental histo-pathology (ICEP) - Genomics and sequencing - Datacentre IT and Scientific Computing - Department of Clinical

Key figures 400 publication/yr Mean IF: 4. 454 SIGAPS score: 3 600 Production 250 200 150 Series 1 2017 2018 Series 3 100 50 0 IF < 5 5 < IF < 10 < IF 15 < IF 20 < IF IF > 30 10 < 15 < 20 < 30 Basic Science Nat. Cell Biol 2012 Nature 2012, 2016 Science 2013 Nat. Str. Mol. Biol. 2013 Nat. Commun. 2014 (2), 2016 (2), 2017 (3) PNAS 2014 (2) EMBO J. 2014, 2015 EMBO Mol Med 2012 PNAS 2014, 2017 (2) J. Immunol. 2012, 2013 PLo. S Genet. 2015, 2017 Cancer Res. 2013, 2015 Mol. Cell. 2015 Clin. Cancer Res. 2013 (2) Cell Rep. 2015, 2016 (2), 2017, 2018 Clin. Cancer Res. 2013 EMBO Mol Med. 2015 Blood 2013 Dev. Cell 2016 JCI 2014, 2016, 2017 Blood 2016 PNAS 2013, 2015 e. Life 2018 Leukemia 2015 (3) Mol. Cell. Prot. 2013, 2015 NAR 2016 Nat. Commun. 2018 Translational Research Clinical Research Ann. Oncol. 2012, 2013 Lancet Oncol. 2012, 2013, 2014, 2015, 2016 Ann. Oncol. 2013, 2014, 2015, 2016 J Clin Oncol. 2012, 2014 NEJM 2018

Clinical research Number of IPC-promoted clinical trials Number of IPC patients included in clinical trials 1600 30 1400 25 1200 1000 20 800 15 600 10 400 5 200 0 0 2013 2014 2015 2016 2017 2013 2014 350 Early phase trials 300 250 number of assays 200 number of IPC patients included 150 100 50 0 2015 2016 2017

Local collaborations and valorization - Canceropôle PACA - Center for Clinical Investigations: - Plan d’Investissement d’Avenir: - Interdisciplinarity: - Industries:

International Collaborations Cancer Research UK Oxford Center - Creation of Marseille Oxford Cancer Center Collaboration (MOC 3) in 2018 1 st joint meeting on Genome (in)stability & Cancer: Oct. 2018 in Marseille 1 st joint call for collaborative proposals: spring 2019 2 nd joint meeting on Pancreatic Cancer: end 2019 in Oxford University of Wisconsin 1 st joint meeting scheduled in 2019 Individual international collaborations: Dresden Technical University, Weizmann Institute, Wisconsin University, Shanghai Institute, Harvard Medical School, University of Helsinki, University of Copenhagen, University of Bergen, Karolinska Institute…

Other training initiatives • • • Internal seminars (monthly sessions: 3 presentations) External seminars (weekly) Keynote speakers (monthly) Journal clubs Students days CRCM days (2 days, every other year)